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Abstract
Background: Making tobacco products associated with lower risks available to smokers who would otherwise continue
smoking is recognized as an important strategy towards addressing smoking-related harm. Predicting use behavior is
an important major component of product risk assessment. In this context, risk perception is a possible factor driving
tobacco product uptake and use. As prior to market launch real-world actual product use cannot be observed,
assessing risk perception can provide predictive information. Considering the lack of suitable validated self-report
instruments, the development of a new instrument was undertaken to quantify perceived risks of tobacco and
nicotine-containing products by adult smokers, former smokers and never-smokers.
Methods: Initial items were constructed based on a literature review, focus groups and expert opinion. Data for scale
formation and assessment were obtained through two successive US-based web surveys (n = 2020 and 1640 completers,
respectively). Psychometric evaluation was based on Rasch Measurement Theory and Classical Test Theory.
Results: Psychometric evaluation supported the formation of an 18-item Perceived Health Risk scale and a 7-item
Perceived Addiction Risk scale: item response option thresholds were ordered correctly for all items; item locations in
each scale were spread out (coverage range 75–87%); scale reliability was supported by high person separation indices
> 0.93, Cronbach’s alpha > 0.98 and Corrected Item-Total Correlations > 0.88; and no differential item functioning was
present. Construct validity evaluations met expectations through inter-scale correlations and findings from known-
group comparisons.
Conclusions: The Perceived Risk Instrument is a psychometrically robust instrument applicable for general and
personal risk perception measurement, for use in different types of products (including cigarettes, nicotine replacement
therapy, potential Modified Risk Tobacco Products), and for different smoking status groups (i.e., current smokers with and
without intention to quit, former smokers, never smokers).
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Background
Cigarette smoking causes many serious diseases [1]. The
best way to reduce the adverse health consequences of
smoking is to stop smoking [2]. For smokers who choose to
continue to smoke, reducing exposure to toxicants and
safer delivery of nicotine are among the strategies that have
been introduced to reduce the risk of smoking-related
diseases [3]. As new tobacco products, which may be a less
harmful alternative to continued smoking, become increas-
ingly available (e.g., smokeless tobacco, e-cigarettes,
heat-not-burn products), this has created new challenges
for policy makers [4]. In the United States (US), a regulatory
framework has been put in place since 2012 for manufac-
turers to market a modified risk tobacco product (MRTP)
– that is, any tobacco product that is sold or distributed for
use to reduce the risk of tobacco-related disease associated
with commercially marketed tobacco products [5].
As population health impact is a function of product
risk and product uptake distribution, predicting product
use prior to market launch is an important component of
product risk assessment. In particular, the effect that an
MRTP’s marketing will have on consumer understanding
and perception is an important consideration as it is
essential that the product communication materials be an
accurate, non-misleading, and scientifically substanti-
ated reflection of the product characteristics, permit-
ting adult smokers to understand the risks and
benefits compared to other tobacco products, without
encouraging non-smokers to initiate or reinitiate to-
bacco use [6]. Part of validating these requirements is
the assessment of consumer risk perception, as such
perceptions might be crucial determinants of product use
among both current tobacco users and non-users [7, 8].
At the same time, valid instruments to measure consumer
responses to tobacco products are largely lacking [9]
and there is currently no self-report instrument available
that would allow the quantification of perceived risks of
different tobacco and nicotine-containing products [10].
A self-report instrument should be: (1) appropriate to
capture the individual perspective and include relevant and
meaningful domains; (2) applicable across a wide range of
tobacco and nicotine-containing products; (3) suitable for a
range of respondent groups such as users and non-users;
(4) underpinned by an appropriate psychometric measure-
ment model; (5) straightforward to administer and score;
and (6) applicable for clinical and population-based studies.
These criteria reflect current standards of valid measure-
ment in terms of qualitative aspects (i.e., relevant and
meaningful domains as evidence of content validity) and
quantitative requirements of construct validity (i.e., psycho-
metric criteria), as well as regarding the practicability and
usefulness. Other desirable psychometric properties in-
clude: unidimensionality (meaning that there is one under-
lying latent variable accounting for the observed item
scores); separation of person and item parameter estimates
(allowing for a detailed examination of the extent to which
a set of items proposed to form a scale separates partici-
pants and allows for precise measurement); and lack of
item bias with respect to subpopulations (thus the proper-
ties of the participants, their distribution and other charac-
teristics, should not impact on the item properties). These
psychometric properties support a metrological framework
for the social sciences, and can be realized by using the
Rasch model which: provides parameter separability, statis-
tical sufficiency, and specific objectivity [11]; is embedded
in Georg Rasch’s general philosophy of measurement [12];
and, is subsequently formalized in the language of measure-
ment traceability [13] and uncertainty [14].
Previous research [10] showed the measurement of per-
ceived risks typically relies on, at most, a small number of
self-report items [9, 15–21]. However, single items, or short
scales, do not allow for a comprehensive measurement of
risk perception, and provide little insight into the underlying
perceived risk continuum. Also, short scales tend to lack
reliability, and, by implication, measurement precision [22].
And psychometric measurement models cannot be easily
applied, limiting the quantitative assessment of construct
validity. Current measurements of perceived risks are typic-
ally product-specific (e.g., for cigarettes) [15, 21, 23–25] or
rely on a single statement of comparative risk between a pair
of products [26, 27]. In the context of an MRTP assessment,
flexible and indirect comparison is needed between all to-
bacco- or nicotine-containing products [5, 28]. Finally, exist-
ing approaches tend to focus on current users (e.g., cigarette
smokers). Considering the lack of suitable validated
self-report instruments, the objective of the present work
was to develop a new instrument to quantify perceived risks
of tobacco and nicotine-containing products by adult
smokers, former smokers and never-smokers. Here, we
describe the overall process and subsequently focus on the
development of two scales addressing Perceived Health Risk
and Perceived Addiction Risk.
Methods
Development of the draft instrument and pre-testing
To support the development of a conceptual framework
and subsequent item generation, a literature review and a
series of qualitative studies were conducted, including focus
groups and expert opinion elicitation. All this qualitative re-
search is described in detailed somewhere else [10], and is
only briefly summarized below. Prior to formal psychomet-
ric evaluation, cognitive debriefing interviews (CDIs) and a
pilot testing were conducted to ascertain the good compre-
hension and acceptability of the draft instrument.
Literature review
A systematic search of studies related to risk perception
and tobacco products published between January 2000
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and September 2012 was conducted in Embase® and
MEDLINE®. Further sources were identified by three
public health experts,1 covering quality of life research,
consumer risk perception research, and scale develop-
ment. A total of 136 papers were identified by database
search, 36 by experts, leading to 42 papers being selected
for a detailed review. The literature review revealed four
broad domains with perceived health risk (including ad-
diction risk) being the most widely captured domain
(referenced in 24 papers). Less frequently, social, finan-
cial, and time-related aspects of perceived risk were ad-
dressed (referenced in 8, 2, and 2 papers, respectively).
Focus groups
In order to gain insights into the respondents’ perspec-
tives, 29 focus groups were conducted in the US, UK,
Italy, and Japan. Smoking status groups were defined in
accordance with the World Health Organization (WHO)
guidelines [29] and the Prochaska and DiClemente stages
of change model [30] (see Table 1 for demographics). In
the focus groups, conventional cigarette, electronic
cigarette and a nicotine replacement therapy (NRT) sam-
ples were used to stimulate participants to discuss risks
associated to tobacco and nicotine-containing products.
The emerging domains showed wide overlap across coun-
tries. Health and addiction risks dominated the concepts
in all countries except in Japan, where societal/social risks
and material/financial risks were about equally prevalent.
Expert opinion
Four experts2 in nicotine addiction, motivational aspects
of consumer perception, and epidemiology proposed
relevant themes and reviewed the identified domains.
Expert opinions widely agreed with the findings of the
literature review and the focus groups and facilitated the
consolidation of all qualitative input to the conceptual
framework. However, experts recommended health risk
to others as a separate aspect of health risk, and addic-
tion risk as a domain on its own. The final conceptual
framework thus comprised five potential domains:
Table 1 Participants in the Focus Groups, Cognitive Debriefing Interviews (CDIs) and Surveys





Male 109 (47.6) 42 (47.7) 932 (46.1) 792 (48.3)
Female 120 (52.4) 46 (52.3) 1088 (53.9) 848 (51.7)
Age (years), Mean ± SD 39.7 ± 12.7 – 45.0 ± 17.4 42.9 ± 16.3
18–25 years, n (%) 34 (14.8) 27 (30.7) na na
26–50 years, n (%) 136 (59.4) 34 (38.6) na na
51–65 years, n (%) 59 (25.8) 26 (29.5) na na
18–30 years, n (%) na na 560 (27.7) 509 (31.0)
31–45 years, n (%) na na 636 (31.5) 544 (33.2)
46+ years, n (%) na na 824 (40.8) 587 (35.8)
Race, n (%)
Caucasian 1628 (80.6) 1309 (79.9)
African-American 152 (7.5) 128 (7.8)
Other 240 (11.9) 203 (12.4)
Education Level, n (%)
High school and less 68 (29.7) 30 (34.1) 705 (34.9) 634 (38.7)
Some college and more 142 (62.0) 58 (65.9) 1315 (65.1) 1006 (61.3)
Other 19 (8.3) – – –
Smoking Status, n (%)
Adult smoker with no intention to quit 71 (31.0) 22 (25.0) 437 (21.6) 408 (24.9)
Adult smoker motivated to quit 39 (17.0) 22 (25.0) 461 (22.8) 408 (24.9)
Adult former smoker 62 (27.1) 22 (25.0) 516 (25.5) 407 (24.8)
Adult never smoker 57 (24.9) 22 (25.0) 606 (30.0) 417 (25.4)
SD standard deviation
aNine focus groups, conducted in London (n = 3), Birmingham (n = 3), and Glasgow (n = 3); Four focus groups conducted in Rome and in Tokyo; Twelve focus
groups, conducted in Atlanta (n = 4), Los Angeles (n = 4) and Philadelphia (n = 4)
bForty CDIs conducted in London (n = 20), Manchester (n = 10), and Glasgow (n = 10); Forty eight CDIs conducted in Atlanta (n = 23) and Los Angeles (n = 25)
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 Perceived Health Risk to Self. The perceived
negative risk (or impact) of product use to the
user’s physical health, ranging from minor
immediate concrete manifestations of health risk
(e.g., having poor gum health) to more serious
long-term ones (e.g., having lung cancer);
 Perceived Addiction Risk. The perceived negative
risk (or impact) that product use may have on the
user’s sense of being addicted to using the product;
 Perceived Health Risk to Others. The perceived
negative risk (or impact) to the physical health of
nonsmokers when being around during product use
(not to be confused with the category of general
risk, i.e., the risk of active use of tobacco products
for active users in general);
 Perceived Social Risk. The perceived negative risk
(or impact) that product use will affect interpersonal
interactions adversely or how the user is perceived
by others;
 Perceived Practical Risk. The perceived negative risk
(or impact) that product use may have on the user’s
time and finances.
Item generation
Two versions of a sentence stem presented at the top of
each page were generated for all items within a domain.
For Perceived Health Risk to Self, one stem referred to
the personal risk to the individual respondent (e.g., with
regards to cigarette smoking: “What do you think is the
risk, if any, to you personally of getting the following
(sometime during your lifetime) because you smoke cig-
arettes …”). The other stem referred to the risk to a user
of a product in general (“In general, what do you think
is the risk, if any, to smokers of getting the following
(sometime during their lifetime) because of smoking cig-
arettes …”). Similar sentence stems were used for other
domains. The items themselves consisted of brief ex-
pressions mostly in the order of four to six words, e.g.,
“having mouth or throat cancer” or “having reduced
stamina”.
A five-point fully verbalized rating scale ranging from
“no risk” to “very high risk” was used to allow for ex-
pressing a medium level of perceived risk (“moderate
risk”). The option “don’t know” was added for respon-
dents not relating to some items and therefore lacking a
perception. Two English language versions of the new
proposed Perceived Risk Instrument (PRI) were drafted for
personal (PRI-P) and general risk assessment (PRI-G). The
intention was that the PRI would be applicable to: (1) adult
smokers with intention to quit, adult smokers with no
intention to quit, adult former smokers, and adult never
smokers; and to (2) tobacco and nicotine-containing prod-
ucts as well as Cessation (perceived risk from having
smoked in the past).
Cognitive debriefing interviews
The draft versions of the PRI-P and PRI-G were presented
to UK and US participants using the same sampling frame
as for the focus groups (Table 1 for demographics). Over-
all, participants found the content to be comprehensive,
the stems to be clear, and the items and response formats
straightforward to complete. Importantly, participants
could discriminate between the two versions of the PRI
and to assess personal as well as general risks accord-
ingly. A few minor changes were made to the draft ver-
sion of the instrument, including: (1) the adjustment of
stems for participants with different smoking status and
for different product types; (2) the removal of two items
in the health risk to others domain due to ambiguity and
lack of relevance; and (3) improvements of the wording of
some items.
In addition, feedback from never smokers suggested
that it was challenging to assess their personal risk of
products (specifically NRT) they would never consider
using. This led to the decision not to administer the
PRI-P to NRT and Cessation to never smokers. The final
draft versions of the PRI comprised a total of 67 items
each, related to five domains: Perceived Health Risk to
Self (31 items); Perceived Health Risk to Others (3 items);
Perceived Addiction Risk (11 items); Perceived Social Risk
(13 items); and Perceived Practical Risk (9 items).
Pilot field testing
After the qualitative stage, the five-domain draft PRI was
administered in a pilot study (web-survey with 233 com-
pleters) to assess the feasibility of developing the five
scales in parallel. Floor effects (between 12 and 41%) oc-
curred for perceived social and perceived practical risks
when applied to products other than cigarettes (CCs). It
was concluded that developing scales for perceived social
and perceived practical risk would in all likelihood, at this
stage, not result in properly targeted scales with a broad
coverage of the latent continuum. Rather, additional quali-
tative research appeared to be necessary. This led to the
decision to, for the time being, solely focus on perceived
health and addiction risks for the psychometric evaluation
of the PRI. Perceived health and addiction risks also were
the most widely addressed domains of risk in the extant
literature [10]. Therefore, the quantitative field tests were
restricted to the three health-related domains, i.e.,
Perceived Health Risk to Self, Perceived Health Risk to
Others, and Perceived Addiction Risk
Psychometric evaluation
For the psychometric evaluation of the draft PRI, two on-
line cross-sectional surveys were conducted in the USA.
Survey 1 served scale formation and item reduction, while
Survey 2 was used for cross-validation of the PRI.
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Design and procedure
Survey 1 and Survey 2 were designed as internet cross-sec-
tional studies with stratified sampling of four subpopula-
tions defined according to self-reported smoking status at
the time of data collection. Respondents reporting having
smoked at least 100 cigarettes in their lifetime and currently
smoking at least one cigarette (no brand restrictions) per
day (disregarding religious fasting) at the time of data col-
lection were classified as adult current smokers. The latter
were further divided into those with, and those without
intention to quit, in accordance to Prochaska and DiCle-
mente’s Stages of Change model [31]. Respondents report-
ing that they were former daily smokers and, at the time of
study, had been quitting smoking more than 30 days ago,
were classified as former smokers. Those who reported that
they had never smoked at all, or who had never been daily
smokers and had smoked less than 100 cigarettes in their
lifetime, were classified as never smokers.
Within each smoking status group, quota sampling based
on age, sex, and education was applied. A web-based data
capture tool (i.e., Confirmit Horizons version 16) was used
to gather responses from study participants from an opt-in
proprietary database maintained by Toluna Group Ltd.
(Wilton, Connecticut USA), consisting of individuals with
expressed interest in participating in online survey research.
The samples within each stratum were not fully representa-
tive in terms of exactly matching the structure of the US
population. Rather, the sample composition served the pur-
pose of scale development and satisfied the needs in this re-
gard, such as adequate representation of each segment
defined by the quota criteria.
In Survey 1, respondents completed the PRI for the as-
sessment objects CC, the Tobacco Heating System (THS)
2.2 (a heat-not-burn Reduced Risk Product (RRP)3 devel-
oped by Philip Morris Products S.A.), a nicotine patch and
Cessation (defined as having successfully stopped smoking
and not using any tobacco and nicotine-containing prod-
uct). In Survey 2, E-cigarettes were added to the assessment
and nicotine patch was replaced by nicotine replacement
therapy (NRT) as a general category. Participants were
quota-randomized to pre-determined sequences so that an
equal number of participants of each demographic stratum
would be exposed to a specific sequence of product assess-
ment. A minimum of 1600 completers, with an equal rep-
resentation of each of the four subpopulations defined by
smoking status, was estimated as an appropriate sam-
ple size for psychometric evaluation for each survey
[22, 32, 33].
Survey 1 (administered between February and March
2014) and Survey 2 (administered between May and June
2014) were both approved by the New England Institu-
tional Review Board and the participants received complete
information about the study before agreeing with an
informed consent form (ICF). The total participation time
for each survey was between 30 and 45 min and partici-
pants were rewarded with 3500 points to exchange for
vouchers or gifts at the reward partner network of the com-
pany hosting the survey (Toluna Group Ltd).
Measurements
Three draft scales each for the PRI-P and PRI-G were
evaluated: Perceived Health Risk to Self (31 items), Per-
ceived Health Risk to Others (3 items), and Perceived Ad-
diction Risk (11 items). A 5-point response scale was used,
with ratings ranging from 1 (no risk) to 5 (very high risk),
additionally offering a “don’t know” option.
Tobacco use history was captured by the Smoking
Questionnaire [34], addressing current and past use of
tobacco-related products. Age, sex, education, income,
and ethnicity were also captured (see Table 1).
In Survey 2, additional measures were administered for
convergent validity assessment: (1) overall measures of the
relative perceived risks associated to the five objects (i.e.,
CC, THS 2.2, E-cigarettes, NRTs, Cessation), based on two
100 mm visual analogue scales (VAS); one for overall
health risk to self and one for overall addiction risk [16,
18]; and (2) five items addressing the participant’s per-
ceived short and long-term consequences of smoking [35].
Data analysis
Survey 1 analyses aimed at identifying the items with the
best psychometric properties. Perceived Health Risk to Self
(31 items) and Perceived Health Risk to Others (3 items)
were initially combined to explore the potential of forming
one inclusive 34-item scale. The internal construct validity
of the items was assessed by Rasch measurement theory
(RMT) analysis, which examined: response scale ordering
(presence of disordered thresholds which are indicative of
inconsistent use of response options); scale targeting (per-
centage of coverage item threshold distribution), model fit
(item and person fit statistics); local dependence (item re-
sidual correlations); reliability (person separation index);
and differential item functioning (DIF) assessed by age, sex,
education, smoking status as well as across different to-
bacco and nicotine-containing products, and across the ap-
plication of the scales to personal risk and risk in general
(see Table 2 for more details on the definitions and accept-
ability criteria for RMTanalysis).
The application of the Rasch model was motivated by
its useful properties such as parameter separation and raw
score sufficiency [36]. Parameter separation ensures
invariance as a consequence of specific objectivity [12] in
the Rasch model. Specific objectivity means that item
characteristics do not depend on the respondents who are
instrumental in their estimation, and vice versa, respond-
ent characteristics are independent of the items used in
their estimation. Hence, comparisons of items, and
respondents, are invariant [37]. In other words, the
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instrument works in the same way for all individuals [38].
Raw score sufficiency proves beneficial from a practical
point of view as it permits a simple raw-score-to-measure
conversion. At this stage, the unrestricted polytomous
Rasch model, also known as the partial credit model, was
used [37].
Classical test theory (CTT) analyses were conducted on
the item-reduced scales resulting from RMT analyses,
including: assessment of data quality (proportion of
missing data as an indication of a lack of acceptabil-
ity); scaling assumptions (similarity of item means and
variances, item-total correlations); scale-to-sample target-
ing (floor and ceiling effects, skewness of item scores); and
internal consistency reliability (Cronbach’s alpha) (see
Table 3 for more details on the definitions and accept-
ability criteria for CTT analysis).
Table 2 Rasch Measurement Theory Analyses: Properties, Definitions and Acceptability Criteria
Property Definitions and Acceptability Criteria
Targeting Targeting refers to the extent to which the range of the target construct measured by each of the scales
(i.e., perceived health risk and perceived addiction risk) matches the range of that target construct
in the study sample. Better targeting equates to a greater ability to interpret the psychometric
data with confidence [50]. This involves examination of the relative distributions of the item
locations and the person measurements as well as of the plot of the person-item location
distributions, showing the item locations and the person measurements on a common scale.
There is no specific criterion. Essentially, the item locations should cover the sample adequately
and the sample should cover the item locations adequately.
Fit The items of the scales of the proposed instrument must work together (fit) as a conformable set,
both conceptually and statistically. Otherwise, it is inappropriate to sum item responses to a total
score and consider the total scale score as a measure of the target construct. When items do not
work together (misfit) in this way, the validity of the scale is questionable [50]. The following
statistical and graphical indicators of fit were investigated [51]:
• Item discrimination: Fit residuals summarize the difference between observed and expected
responses to an item across all respondents (item-person interaction). Fit residuals should
ideally lie within ±2.5. Fit residuals lying outside this range imply misfit of the observed data
to the Rasch model. Negative values indicate overdiscriminating and positive values
underdiscriminating items. Due to the large sample size in Surveys 1 and 2 it was to be
expected to find a substantial number of item misfits, but this indicator was still considered
helpful as some items were expected fitting much worse than others.
• Item fit: Chi-squared values summarize the difference between observed and expected responses
to an item for groups (or ‘class intervals’) of individuals with relatively similar levels of ability
(item-trait interaction). A chi-squared value with a low likelihood (p-value) implies that the
discrepancy between the observed responses and the expected value is large relative to chance
for that item.
• Item response ordering: This involves the examination of the category probability curves (CPCs)
and the threshold probability curves (TPCs) which show the ordering of the thresholds for each
item. A threshold marks the location on the latent continuum where two adjacent response
categories are equally likely. The ordering of the thresholds should reflect the intended order of
the categories lower (‘no risk’) to higher (‘high risk’) values. Correct ordering supports the
assumption that the response categories work as intended. Disordered thresholds indicate that
the response categories for a particular item are not working as intended, and therefore that the
scoring function for that item is not valid.
• Local independence: This involves an examination of item residual correlations [52]. Correlations
between the residuals should be low (< 0.30). In addition, residual correlations are assessed
against the average of all residual correlations plus 0.3 [53, 54]. If residuals for item pairs are
correlated > 0.30, this indicates that the response to one item depends on the response to the
other item, i.e., the items are locally dependent [55].
Reliability Reliability refers to the extent to which scale scores reflect random error [56]. This was assessed using
the person separation index (PSI), which is an internal reliability statistic comparable to Cronbach’s
alpha. The PSI quantifies the error associated with the measurements of individuals in the sample [56].
The PSI ranges from 0 (all error) to 1 (no error). A low PSI implies that scale items are not
able to reliably separating individuals on the scale they define.
Stability Comparability of PRI measures across different factors was based on tests of invariance
(key criterion of successful measurement), implying that items mean the same to different
participant groups under different conditions. This is assessed by means of a test for
differential item functioning (DIF) [57]. Invariance was assessed according to demographic
criteria (age, gender, education) as well as across different tobacco and nicotine-containing
products, different subpopulations based on smoking status and across the application of
the scales to perceived personal risk and perceived general risk. DIF is assessed by comparing
observed residuals (i.e., the difference between expected responses under the assumption of
no DIF and actually observed responses) across groups of participants defined by the DIF factor
investigated (e.g., males versus females) and classified in several class intervals along the
latent continuum measured by the scale.
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Survey 2 analyses replicated the same analyses on the
item-reduced scales obtained from Survey 1 for cross-valid-
ation with an independent sample. In addition, construct
validity (i.e., convergent and known-group) was evaluated.
Convergent validity was assessed by non-parametric corre-
lations with individual items of related measures (i.e.,
VAS on overall health risk; VAS on addiction risk and the
five items on short and long-term consequences of smok-
ing). PRI score differences between respondent groups that
were expected to differ based on subject matter consider-
ations (known-group validity) were assessed with t-tests.
The group differences examined were: (1) perceived per-
sonal versus general risk among current smokers (with per-
ceived personal risk expected to be lower) [39, 40]; (2)
current versus never smokers (with perceived risk of smok-
ing expected to be lower for current smokers) [40]; and (3)
between smokers with versus without intention to quit
(with perceived risk of smoking in smokers intending to
quit expected to be higher) [41].
To explore the extent to which the PRI scores were influ-
enced by the position of the assessment object in the se-
quence, mean scores were calculated by object, sequence
and smoking group for all PRI scales, based on RMT logit
measures transformed into a 0–100 score. Since the number
of sequences was very large (120 possible sequences), the as-
sessment of sequence effects was based on pairwise compar-
isons of objects using t-tests for independent samples [42].
RMT analyses were performed using RUMM2030 and
all other analyses were performed with SPSS (version 21).




The baseline characteristics of the 2020 and 1640 partici-
pants who completed Survey 1 and Survey 2, respectively,
are summarized in Table 1. Due to the quota sampling,
similar numbers of males and females completed the sur-
veys (46% and 48% of males respectively). Between 61% and
65% of the participants had a high school or higher educa-
tion and slightly more participants completed Survey 1 in
the 46+ years of age group (41% and 36%, respectively).
In both surveys, most participants categorized them-
selves as Caucasians (81% and 80%, respectively). Dis-
position of participants in Survey 1 and 2 is presented
in Table 4.
Scale formation and item reduction (Survey 1)
The 34 items assessing Perceived Health Risk demon-
strated no disordered thresholds, reasonable coverage of
the item thresholds (88%) and good reliability as assessed
by the PSI of 0.97 (Table 5). Through a series of three iter-
ations, a total of 16 items were removed from the initial
item pool. Although the psychometric red flags were
Table 3 Classical Test Theory Analyses: Properties, Definitions and Acceptability Criteria
Property Definitions and Acceptability Criteria
Data quality Data quality refers to the extent to which the scale items are accepted by the participants and, consequently,
yield usable responses. Missing data are indicative of a lack of acceptability and/or a lack of applicability of the
items from the perspective of the participant. Item-level missing data should be < 10% [58]
Scaling assumptions Scaling assumptions refer to the extent to which it is legitimate to sum a set of item scores, without weighting
or standardisation, to produce a single total score [59, 60]. Summing scale item scores is considered legitimate,
when the items:
• are approximately parallel (i.e., they measure at the same point on the scale). This criterion is satisfied
when items have similar mean scores [61];
• contribute similarly to the variation of the total score (i.e., they have similar variances), otherwise they
should be standardized. This criterion is satisfied when items have similar standard deviations [62];
• measure a common underlying construct, as otherwise combining them to produce a single score is
not appropriate [63]. This criterion is satisfied when items have adequate corrected item-total correlation
(ITC ≥ 0.30) [64];
• contain a similar proportion of information concerning the construct being measured. Otherwise items
should be given different weights [61]. This criterion is satisfied when items have similar ITCs [64].
Scale-to-sample
targeting
Scale-to-sample targeting refers to the extent to which the range of the construct measured by the scale
matches the range of that variable in the study sample. Adequate targeting provides greater confidence
in making judgments about the performance of the scale when interpreting results. Poor targeting implies
that measurement precision is limited. People with extreme scores represent a sub-sample in which changes
within and differences between individuals will be underestimated. Scale scores should span the entire range;
floor (proportion of the sample at the minimum score for the scale) and ceiling (proportion of the sample at
the maximum score) effects should be low (< 15%) [65]; and skewness, i.e., the third central moment of
the distribution capturing its asymmetry, should be between ±1 [66]. There are no published criteria for
item-level targeting.
Reliability Reliability refers to the extent to which scale scores reflect random error. High
reliability indicates that scores are associated with little random error, i.e., are consistent. Internal
consistency reliability estimates the random error associated with total scores from the intercorrelations
among the items [67]. The recommended level for adequate scale internal consistency is Cronbach’s
alpha coefficient≥ 0.80 [67], and item-total correlations > 0.30 [58].
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misfit (n = 9), and uniform DIF (n = 7), the totality of evi-
dence to support the extent to which scales were fit for
purpose (i.e., conceptual clarity, contexts of use, intended
application and use cross cultural studies) was leveraged
in each instance to make the final decisions in relation to
item retention. A re-analysis of the reduced 18-item Per-
ceived Health Risk scale (for items see Table 6) revealed
that the scale performed appropriately (i.e., no disordered
threshold, no DIF for any of the subgroups tested, cover-
age of 84% of participants, and a PSI of 0.97; Table 5).
Psychometric performance based on CTT methods
was also strong: skewness of 0.05; Cronbach’s alpha of
0.99; and corrected Item-Total Correlations ranging
from 0.89 to 0.93 (Table 7). The percentage of missing
data was 0.1% at most at the item-level, demonstrating
high acceptability of the PRI. The proportion of “don’t
know” responses was between 11% and 15%. While
“don’t know” responses were valuable qualitative infor-
mation, they had to be treated as missing data in the
psychometric analysis. However, the observed propor-
tion of “don’t know” responses had no adverse
consequences for parameter estimation and scale evalu-
ation, given the large number of responses in total.
The 11 items assessing Perceived Addiction Risk
showed no disordered item thresholds, reasonable cover-
age of the item thresholds (80%) and good reliability with
a PSI of 0.94 (Table 5). Three items showed misfit and one
item uniform DIF. Once again, we leveraged all the avail-
able evidence to decide on item retention. A re-analysis of
the reduced 7-item Perceived Addiction Risk scale (for
items see Table 6) revealed that the scale performed ap-
propriately (Table 5). Among the seven items, three are
applicable for all objects but for Cessation. One item
(feeling anxiety when in a situation where people smoke)
was retained for administration only for Cessation (4-item
scale for Cessation and 6-item scale for all other tobacco
and nicotine-containing products). A re-analysis of the
reduced 7-item Perceived Addiction Risk scale revealed
that the scale performed appropriately: No disordered
thresholds, no DIF for any of the subgroups tested, cover-
age of 75% and a PSI of 0.93 (Table 5). Psychometric
performance based on CTT methods was also strong:
Skewness of − 0.41; Cronbach’s alpha of 0.98; Corrected
Item-Total Correlations ranging from 0.90 to 0.93 (Table
7). The item-level missing data percentages were at 0.1%
at most. At the item level, the proportion of “don’t know”
responses was between 8% and 12%.
For both the Perceived Health and Addiction Risk scales,
the personal versus general risk versions performed equiva-
lently from a psychometric point of view (i.e., no DIF).
Psychometric cross-validation (Survey 2)
The analysis of the Survey 2 18-item Perceived Health
Risk scale data revealed that the scale performed
Table 4 Participant Disposition in Surveys 1 and 2




Accessed the survey 11,914 14,904
Enrolled in the survey 2411 2400
Completed the survey 2020 1640
Dropped out during the survey 391 760
Not enrolled because of
inclusion/exclusion criteria violation
2512 2764
Not enrolled because of full quota 3082 4312




























Survey 1 Long Form Scales
Health Risk (34) 88 94 21 0 16/595 24/595 50 0.97
Addiction Risk (11) 80 82 18 0 3/49 4/49 9 0.94
Survey 1 Reduced Scales
Health Risk (18) 84 61 0 0 0/153 13/153 0 0.97
Addiction Risk (7) 75 86 0 0 0/18 2/18 0 0.93
Survey 2 Reduced Scales
Health Risk (18) 87 72 0 0 0/153 8/153 0 0.97
Addiction Risk (7) 78 86 0 0 0/18 1/18 0 0.94
PSI person separation index, χ2 Chi-square, DIF differential item functioning
aThe high percentages were expected given the large sample size but are still informative when some items are much worse fitting relative to others
bIn the statistical assessment the actual n was adjusted to 500 in order to mitigate excessive power and for parallel fit assessment based on a sample size of 500,
which is deemed appropriate for the present psychometric analysis
cThe critical values for residual correlations were 0.268 and 0.188, respectively, for Survey 1 Long Form Scales; 0.146 and 0.058, respectively, for Survey 1 Reduced
Scale: and 0.169 and 0.057, respectively, for Survey 2 Reduced Scales
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appropriately: no disordered thresholds; no DIF; 87% of
coverage of participants; and a PSI of 0.97 (see Table 5
for summary statistics and Table 6 for item statistics).
Psychometric performance based on CTT methods was
also strong: skewness 0.02; Cronbach’s alpha of 0.99; and
Corrected Item-Total Correlations ranging from 0.88 to
0.92 (Table 7).
At the item-level, the percentage of missing data was
0.1% at most, confirming very high acceptability of the PRI.
Among completers, 99% of the study participants provided
responses to all items, including the “don’t know” option,
the latter being treated as missing data in the psychometric
analysis. At the item level, the proportion of “don’t know”
responses was in the range of 12% and 14%. The item
thresholds ranged between − 4.5 and + 4.0 providing for a
broad area where the scale was effective allowing for precise
and interpretable measurement.
The 7-item Perceived Addiction Risk scale showed no
disordered item thresholds, reasonable coverage of the
category thresholds (78%) and good reliability with a PSI
of 0.94 (see Table 5 for summary statistics and Table 6 for
item statistics). Psychometric performance based on CTT
methods was also strong: Skewness of − 0.32; Cronbach’s
alpha of 0.98; Corrected Item-Total Correlations ranging
from 0.92 to 0.95 (Table 7). As for the Perceived Health
Risk Scale, the item-level missing data percentages were at
0.1% at most. At the item level, the proportion of “don’t
know” responses was between 8% and 13%. The item
thresholds of the Perceived Addiction Risk scale ranged
between − 5.4 and + 5.3 providing for a broad area where
the scale was effective allowing for precise and interpret-
able measurement.
Construct validity (Survey 2)
For the assessment objects CC, THS 2.2, E-cigarettes and
NRT, all correlations between the VAS scores and PRI
measures for both Perceived Health Risk and Perceived
Addiction Risk were in the range of 0.52 to 0.68 across
both types of risk (i.e., personal and general; Table 8).
Table 6 PRI Health and Addiction Risk Items







PRI Perceived Health Risk
Cough lasting for days 0.150 0.021 4.612 0.867
Gum health 0.035 0.022 2.275 0.986
Lung cancer − 0.477 0.021 7.998 0.534
Wheezing −0.193 0.021 1.421 0.998
Mouth throat cancer −0.058 0.022 0.931 1.000
Aging faster −0.015 0.021 0.445 1.000
Minor illnesses 0.176 0.022 1.968 0.992
Respiratory infection −0.051 0.022 5.752 0.764
Serious illness 0.049 0.022 4.425 0.881
Reduced stamina 0.135 0.022 2.138 0.989
Emphysema −0.132 0.021 3.447 0.944
Cough in the morning 0.045 0.021 2.879 0.969
Sense of taste −0.288 0.022 3.543 0.939
Heart disease −0.147 0.021 0.817 1.000
Earlier death 0.426 0.022 5.717 0.768
Sores mouth throat 0.319 0.022 4.140 0.902
Unfit 0.001 0.022 0.824 1.000
Other cancer 0.150 0.021 4.612 0.867
PRI Perceived Addiction Risk
Being unable quit 0.428 0.028 6.203 0.719
Feeling addicted −0.133 0.025 6.343 0.705
To feel better 0.311 0.026 2.750 0.973
Feeling like have to smoke 0.105 0.026 4.742 0.856
Cannot stop 0.230 0.028 3.665 0.932
Feeling unable quit 0.097 0.028 2.853 0.970
Anxiety situation people smoke −1.038 0.054 10.612 0.303
aFull item wording available through MAPI Research Trust
bp values based on a random sample of n = 500























Health Risk (18) 11–15 18–90 54.4 (22.32) 0.89–0.93 7/10 0.05 0.99 0.83 0.76–0.90
Addiction Risk (7) 8–12 6–30 20.7 (7.50) 0.90–0.93 8/20 −0.41 0.98 0.87 0.82–0.91
Survey 2
Health Risk (18) 12–14 18–90 56.1 (20.46) 0.88–0.92 5/10 0.02 0.99 0.81 0.75–0.89
Addiction Risk (7) 8–13 6–30 20.6 (7.09) 0.92–0.95 6/18 −0.32 0.98 0.89 0.85–0.93
SD standard deviation, CITC corrected item-total correlation, IIC inter-item correlation
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Assuming a reliability of the VAS of 0.6 and applying the
Spearman Brown formula [43] for disattenuation imply
correlations in the order of 0.68 and 0.89.
Correlations of the 18-item Perceived Health Risk
measure with all five items on short- and long-term con-
sequences of smoking were all in the expected direction
for both personal and general risk (Table 9). Correlations
were mostly weak to moderate, regardless of smoking
status and type of risk, with absolute values ranging
from 0.10 to 0.40 for personal risk and from 0.20 to 0.46
for general risk. The size of these correlations was not
expected to be very high given the specific content of
the individual items of the short- and long-term conse-
quences of smoking questionnaire. Importantly, correla-
tions were of similar magnitude across items focusing
on short-term (first three items) or long-term conse-
quences of smoking CC (last two items). This provides
strong evidence that the 18-item Perceived Health Risk
scale is balanced in terms of short- and long-term risks.
Descriptive statistics of the PRI scales by object
(Table 10) showed that the perceived risk of CC was al-
ways the highest for both Perceived Health Risk and for
Perceived Addiction Risk. This was true for personal and
general risk. The risk of THS 2.2 was uniformly consid-
ered second-highest after CC. E-Cigarettes were per-
ceived to be less risky compared to THS 2.2. The
perceived risks of NRT and Cessation generally marked
the lower end. Since the risks associated with NRT re-
ferred to the risk of using NRT for a certain period of
time in the future, while Cessation meant the perception
of incurred risks of smoking CC in the past, this could
explain that NRT was perceived as more risky than Ces-
sation. It might seem obvious to compare the levels of
observed perceived risk with actual objective risk as an-
other way of assessing convergent validity of the PRI. In-
deed, the perceived risk of ongoing use of CC was
clearly higher than Cessation or using NRT, which was
in line with what one would have expected. However,
the evaluation of objective risk of E-cigarettes is still a
matter of ongoing research and no final assessment has
been made yet. Even less is known about the objective
risk of THS 2.2. Thus, the potential to compare per-
ceived risks and objective risk is limited. In fact, the lack
of objective evidence of risks associated with using THS
2.2 was one of the main reasons to develop the PRI.
With respects to known-group validity, all mean differ-
ences were in the expected direction. In terms of the
effect sizes (Cohen’s d), differences between smokers
and never smokers were more pronounced than differ-
ences between personal and general risk among current
smokers (Table 11). Regarding the differences between
current smokers with and without intention to quit,
known-group validity was confirmed as well by the
perceived risk being higher for smokers with quitting
intention.










































CC Conventional cigarettes, E-CIG Electronic cigarettes, n number of study
participants with both measurements, NRT Nicotine Replacement Therapy,
PRI-p Perceived Risk Instrument-Personal Risk, PRI-G Perceived Risk Instrument-
General Risk, rs Spearman rank correlation coefficient, THS Tobacco Heating
System, VAS Visual Analog Scale
Table 9 Convergent Validity of PRI 18-Item Health Risk Scale (CC) with Items from the Short- and Long-Term Smoking Risks Questionnaire
(Spearman Correlation Coefficients, Survey 2)























Item 1 −0.35 − 0.26 −0.40 − 0.21 − 0.21 −0.30 − 0.29 −0.29 − 0.20 −0.33
Item 2 0.33 0.34 0.28 0.24 0.35 0.39 0.26 0.45 0.31 0.45
Item 3 −0.28 −0.27 −0.34 − 0.14 −0.14 −0.29 − 0.26 −0.24 − 0.23 −0.25
Item 4 −0.28 −0.30 − 0.37 −0.10 − 0.13 − 0.28 −0.27 − 0.29 −0.24 − 0.23
Item 5 0.30 0.18 0.18 0.28 0.37 0.41 0.29 0.39 0.36 0.46
CS IQ current smokers with intention to quit, CS NIQ current smokers with no intention to quit, FS former smokers, NS never smokers, n number of study
participants with both measurements, PRI-P Perceived Risk Instrument-Personal Risk, PRI-G Perceived Risk Instrument-General Risk
Item 1: There is really no risk at all for the first two years
Item 2: Every single cigarette smoked causes a little bit of harm
Item 3: Although smoking may eventually harm this person’s health, the very next single cigarette he or she smokes will probably not cause any harm
Item 4: Harmful effects of smoking rarely occur until a person has smoked steadily for many years
Item 5: Smoking at the daily rate of one package of cigarettes each day will eventually harm this person’s health
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Carry-over effects (Survey 2)
For the assessment objects CC, THS 2.2 and E-cigarettes
no differences were detected between measures of Per-
ceived Health Risk when the product was presented first
versus second or later (Table 12). However, for Cessation,
both personal and general Perceived Health Risk were
higher when Cessation was presented as the first assess-
ment object compared to it being presented after any
other assessment. For NRT, a similar effect was found for
perceived general risk, with the level of perceived risk be-
ing higher when NRT was assessed first.
Discussion
The psychometric performance of the PRI was strong
across both RMT and CTT analyses, supporting the con-
clusion that the 18-item Perceived Health Risk scale and
the 7-item Perceived Addiction Risk scale are reliable
and psychometrically valid. Construct validity evalua-
tions of both scales met expectations through inter-scale
correlations and findings from known-group compari-
sons. At the same time, the assessment of convergent
validity was limited due to the absence of an undisputed
gold standard measure for perceived risk assessment.
Specifically, no definitive assessment of objective risks of
products, such as E-Cigarettes or THS 2.2, has been
made that would allow to compare objective and per-
ceived risks. The PRI scale measures were correlated
with single items (VAS or items from the short- and
long-term consequences of smoking questionnaire),
resulting overall in moderate convergent validity, mostly
due to the lack of reliability of single items compared to
PRI scale measures.
To enable appropriate use of the PRI, the final outcome
of the present study was the development of a calibrated
scoring table (available through MAPI Research Trust),
based on weighted likelihood estimation (WLE) [44].
Table 10 PRI Health and Addiction Object Means
Instrument: Type of Risk Domain Object Rasch-Based
(logits)
Mean (SD)
PRI-P: Personal Perceived Health Risk CC (n = 773) 2.12 (3.19)
THS 2.2 (n = 718) 0.51 (3.17)
E-CIG (n = 726) −0.15 (3.36)
NRT (n = 556) −1.47 (3.15)




CC (n = 770) 2.91 (3.51)
THS 2.2 (n = 706) 1.23 (3.66)
E-CIG (n = 712) 0.61 (3.88)
NRT (n = 537) −0.30 (3.62)
CESS, towards





CC (n = 778) 2.51 (2.88)
THS 2.2 (n = 716) 0.63 (2.97)
E-CIG (n = 728) −0.17 (3.06)
NRT (n = 718) −0.70 (3.12)




CC (n = 773) 3.73 (3.06)
THS 2.2 (n = 703) 1.69 (3.46)
E-CIG (n = 715) 0.75 (3.40)
NRT (n = 705) 0.30 (3.29)
CESS, towards
CC (n = 753)
−0.04 (3.32)
CC Conventional cigarettes, CESS Cessation, E-CIG Electronic cigarettes, NRT
Nicotine Replacement Therapy, PRI Perceived Risk Instrument, SD standard
deviation, THS 2.2 Tobacco Heating System 2.2
Table 11 Known-Group Validity: Comparison of Perceived






SD t (df) p-value Cohen’s
d
Differences between personal and general risk
PRI-P CS (all) 397 1.26 2.88 2.50 (785) 0.013 0.18
PRI-G CS (all) 390 1.77 2.88
PRI-P CS NIQ 194 0.93 2.96 1.21 (385) 0.227 –
PRI-G CS NIQ 193 1.29 2.93
PRI-P CS IQ 203 1.58 2.76 2.42 (398) 0.016 0.24
PRI-G CS IQ 197 2.25 2.76
Differences between current smokers and never smokers
PRI-P CS (all) 397 1.26 2.88 6.28 (579) <.001 0.53
NS 184 3.05 3.80
CS NIQ 194 0.93 2.96 6.08 (376) <.001 0.62
NS 184 3.05 3.80
CS IQ 203 1.58 2.76 4.39 (385) <.001 0.44
NS 184 3.05 3.80
PRI-G CS (all) 390 1.77 2.88 7.53 (580) <.001 0.68
NS 192 3.65 2.69
CS NIQ 193 1.29 2.93 8.22 (383) <.001 0.84
NS 192 3.65 2.69
CS IQ 197 2.25 2.76 5.06 (387) <.001 0.51
NS 192 3.65 2.69
Differences between CS IQ and CS NIQ
PRI-P CS IQ 203 1.58 2.76 2.28 (395) 0.023 0.23
CS NIQ 194 0.93 2.96
PRI-G CS IQ 197 2.25 2.76 3.33 (388) 0.001 0.34
CS NIQ 193 1.29 2.93
CS IQ current smokers with intention to quit, CS NIQ current smokers with no
intention to quit, FS former smokers, NS never smokers, PRI-P Perceived Risk
Instrument-Personal Risk, PRI-G Perceived Risk Instrument-General Risk, SD
standard deviation. Cohen’s d indicated for p-values < 0.05
Cano et al. Health and Quality of Life Outcomes  (2018) 16:192 Page 11 of 15
Given the participant raw scores and item parameters, the
calibration was done with the restricted Rasch model for
polytomous responses [45, 46]. For complete data, the
resulting conversion table transfers sum scores to logit
measures, which are mapped to a 0–100 scale for conveni-
ence. The conversion is a simple linear transformation
that changes the logit mean of 0 to 50 and converts the
most extreme measures to 0 and 100, respectively.
The application of the Rasch model for measurement
[45, 46] implied that item discrimination was supposed to
be the same across all items in a scale. While this property
of the model provides for invariance in the parameters of
the model as an advantageous property facilitating
generalizability, it undoubtedly represents a restriction to
the data. More general item response theory (IRT) models,
such as the Generalized Partial Credit model [47], account
for different item discrimination by estimating additional
parameters. However, in the case of the PRI, the assump-
tion of equal discrimination was empirically supported.
Therefore, estimating discrimination parameters would
have run contrary to the general scientific principle of par-
simony and would not have significantly improved the fit of
the model to the data.
The relatively high item-intercorrelations (between 0.75
and 0.89 for Perceived Health Risk in Survey 2; Table 7)
could be of concern as a potential indication of item redun-
dancy. However, no specific pair of items stood out with
respect to the item-intercorrelation. Rather, the high correla-
tions were a result of consistency in the response patterns
and high measurement precision. What is more, redundancy
was a key criterion in the data analysis by examining
residual correlations. In the item reduction phase, any
potential duplication of content was thoroughly considered
ensuring that the final scales lack any redundancy.
There are four key strengths in this instrument devel-
opment program. First, the content validity of the new
instrument (that is the scale scores represent the con-
cepts of interest, and the instructions and item content
are appropriate, comprehensive and understandable to
the target population) was evidenced by information
gathered from literature review, focus groups, expert
opinions, cognitive debriefing interviews, and pilot field
testing.
Second, the design of the quantitative studies included a
broad range of subpopulations in the US in terms of
smoking status, considering current and past smoking
behaviour as well as intentions to quit smoking cigarettes.
The diversity of subpopulations provided a broad frame of
reference for which the validity of the PRI could be
demonstrated. In addition, the sample design provided an
approximately equal representation of all four smoking
status groups, ensuring adequate psychometric analysis
for all groups. Within each smoking status group, add-
itional stratification allowed for the assessment of measure-
ment equivalence across age groups, sex and levels of
education. The psychometric cross-validation with an inde-
pendent sample and the large total sample size support a
robust psychometric quality of the items.
Third, the fit of the data to the unidimensional meas-
urement model and the lack of DIF by assessment object
demonstrate that the items for each scale worked as a set,
representing manifestations of unidimensional perceived
health and addiction risks, respectively, for a diversity of
products, i.e., combustible cigarettes, heat-not-burn prod-
uct, e-cigarettes, nicotine replacement therapy products as
well as Cessation. Therefore, the instrument development
provides a solid foundation for the scales to be used with
other products (e.g., different potential RRPs). Nevertheless,
for application of the PRI to products substantially different
to those assessed here, such as smokeless tobacco, reinves-
tigating the validity of the scales is advisable. In particular,
Table 12 Assessment of Carry-Over Effects (Perceived Health
Risk Scale Survey 2)
Sequence n Mean
(logit)
































NRT first 110 −1.35 2.85 −0.42
(554)
0.672 –
NRT subsequently 446 −1.49 3.22







CC first 162 2.89 2.75 −1.89
(776)
0.060 –
CC subsequently 616 2.41 2.91












NRT first 140 −0.21 2.85 −2.10
(716)
0.037 0.20
NRT subsequently 578 −0.82 3.17






CC Conventional cigarettes, CESS Cessation, E-CIG Electronic cigarette, NRT
Nicotine Replacement Therapy, PRI-P Perceived Risk Instrument-Personal Risk,
PRI-G Perceived Risk Instrument-General Risk, THS 2.2 Tobacco Heating System
2.2. Cohen’s d indicated for p-values < 0.05
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the comparability of the perceived risk measures with those
related to products considered in the scale development
project should be assessed at the item level by DIF analyses.
Fourth, the instrument development accounted for
two types of risk perceptions: personal risk (risk to the
individual respondent) and general risk (risk to users of
the products in general). Both personal (PRI-P) and gen-
eral (PRI-G) versions of the instrument performed
equally well from a psychometric point of view, implying
that either of the two could be used in future studies,
depending on the design and objective.
There are also some limitations to our study. First, web
panels are not fully representative of the US population.
In particular, a bias towards higher education is a typical
and widespread phenomenon in panel-based online sur-
veys [48]. In order to mitigate this limitation, education
was included as a sampling quota. The relative simplicity
of the items, their high comprehensibility as demonstrated
in the CDIs and the very low rates of non-completers
dropping out of the survey prematurely suggest the suit-
ability of the PRI for a broad range of educational levels.
This conclusion was also supported by evidence from the
psychometric analyses, with DIF analyses confirming that
the scales work equivalently for participants with higher
and lower education.
Second, as the study was administered as a web survey,
all psychometric findings are in principle confined to this
mode of administration. As a suggestion for future re-
search, the administration of the PRI as a paper-and-pencil
questionnaire or as a telephone interview should involve a
cross-method comparison of the psychometric properties.
The likelihood of the validity of the PRI to be maintained
when administered in modes other than online, particu-
larly through paper-and-pencil, is deemed high, as the
instruments proved very stable in terms of diverse sub-
populations (e.g., based on smoking status) and objects
(products, behaviours). The simplicity of the items them-
selves also contributes to high comprehensibility of the
PRI, as demonstrated in the qualitative phase (cognitive
debriefing interviews), which indeed included the presen-
tation of the instruments on paper.
Third, the assessment of perceived health risks concern-
ing different types of tobacco and nicotine-containing
products was not completely free of carry-over effects. In
principle, fit of the data to the Rasch model supports speci-
fically objective measurement and, thus, invariance. How-
ever, specific objectivity only applies within a frame of
reference, for which invariance of comparisons has been
empirically demonstrated [49]. The analysis of repeated
measurements of perceived risks provided evidence that
the study design may jeopardize invariance and, therefore,
comparability of measures. The assessment of one type of
tobacco and nicotine-containing product may have a prim-
ing effect on the subsequent assessment of another product.
Studies applying the PRI in a repeated measurement design
should thus take the potential of carry-over effects into ac-
count, particularly if perceived risks of Cessation and of
NRTs are to be assessed. Our findings suggest that these ef-
fects may best be accommodated by a fixed order of objects
presented to the participants. The best-known product
should be presented first, to set a meaningful reference
point. Thereafter, tobacco products should be presented by
decreasing familiarity. Based on the principle of moving
from use of products to their non-use, objects related to
quitting smoking should be presented last, with Cessation
(not involving any use of NRT) to be presented as the very
last object.
Finally, a possible concern when applying the PRI to
multiple objects in a repeated measurement design could
be response burden. However, the structural simplicity
of the PRI consisting of items that are brief statements
allows for a straightforward and fast completion (less
than 5 min per object). We did consider a shorter
9-item version of the Perceived Health Risk scale. In
terms of traditional reliability, the short version would
only be slightly less reliable. The standard error of meas-
urement for an individual respondent, though, would in-
crease by up to about 80%, depending on the level of
perceived risk. Given the predominant role of perceived
health risk from a respondent’s perspective, we therefore
recommend the application of the full 18-item scale.
Conclusions
By quantifying perceived tobacco and nicotine-containing
product risks, the PRI fills an important methodological
gap and may be used in clinical and population-based
studies. Based on the structured development process and
the amount of validation data, the PRI can be a valuable
self-report instrument that provides a scientifically rigorous
method to quantify the perceived risks of tobacco and
nicotine-containing products and related behaviors. With
increasing numbers of researchers incorporating the PRI
into their studies, we envision a rapidly expanding
knowledge-base, informing further interpretation of risk
perception data comparing a large spectrum of tobacco and
nicotine products, so that the health and public policy
communities can make more informed decisions on the
potential public health impact of MRTPs. Such data will
provide meaningful information on: (1) the effects of risk
perception on tobacco and nicotine-containing product use
behavior among current tobacco users; (2) the effects on
product use initiation among non-users; and (3) the effects
of risk communication on consumer understanding and
perception.
Endnotes
1The three experts involved in the literature review have
strong expertise in public health and quality of life,
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consumer risk perception, qualitative and quantitative re-
search in scale development. They currently hold, or previ-
ously held, positions at governmental regulatory bodies,
universities or contract research organisations.
2The four experts involved at this stage were subject mat-
ter key opinion leaders (KOLs) in fields of nicotine and
other addictions, motivational aspects of consumer percep-
tion, in epidemiologic study design, data management, and
evaluation, measurement of clinical concepts, evidence-
based medicine, and statistical analysis in health. All ex-
perts hold leading positions at universities or organisa-
tions in health care in the USA or Canada. The KOLs
have a long record of publications in the healthcare sector
and have contributed to governmental programs at treating
various kinds of addictions in public health. None of the
four experts was involved in the previous literature review.
3Reduced Risk Products (“RRPs”) is the term used by
Philip Morris Products S.A. to refer to products with the
potential to reduce individual risk and population harm
in comparison to smoking cigarettes. More details are
available on www.pmiscience.com.
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